Abstract:Breast cancer (BC) is a common cause of morbidity and mortality, particularly in women. Moreover, the discovery of diagnostic biomarkers for early BC remains a challenging task. Previously, we [Jasbi et al. J. Chromatogr. B. 2019, 1105, 26-37] demonstrated a targeted metabolic profiling approach capable of identifying metabolite marker candidates that could enable highly sensitive and specific detection of BC. However, the coverage of this targeted method was limited and exhibited suboptimal classification of early BC (EBC). To expand the metabolome coverage and articulate a better panel of metabolites or mass spectral features for classification of EBC, we evaluated untargeted liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) data, both individually as well as in conjunction with previously published targeted LC-triple quadruple (QQQ)-MS data. Variable importance in projection scores were used to refine the biomarker panel, whereas orthogonal partial least squares-discriminant analysis was used to operationalize the enhanced biomarker panel for early diagnosis. In this approach, 33 altered metabolites/features were detected by LC-QTOF-MS from 124 BC patients and 86 healthy controls. For EBC diagnosis, significance testing and analysis of the area under receiver operating characteristic (AUROC) curve identified six metabolites/features [ethyl (R)-3-hydroxyhexanoate; caprylic acid; hypoxanthine; and m/z 358.0018, 354.0053, and 356.0037] with p < 0.05 and AUROC > 0.7. These metabolites informed the construction of EBC diagnostic models; evaluation of model performance for the prediction of EBC showed an AUROC = 0.938 (95% CI: 0.895-0.975), with sensitivity = 0.90 when specificity = 0.90. Using the combined untargeted and targeted data set, eight metabolic pathways of potential biological relevance were indicated to be significantly altered as a result of EBC. Metabolic pathway analysis showed fatty acid and aminoacyl-tRNA biosynthesis as well as inositol phosphate metabolism to be most impacted in response to the disease. The combination of untargeted and targeted metabolomics platforms has provided a highly predictive and accurate method for BC and EBC diagnosis from plasma samples. Furthermore, such a complementary approach yielded critical information regarding potential pathogenic mechanisms underlying EBC that, although critical to improved prognosis and enhanced survival, are understudied in the current literature. All mass spectrometry data and deidentified subject metadata analyzed in this study have been deposited to Mendeley Data and are publicly available (DOI: 10.17632/kcjg8ybk45.1).

Evaluation of Untargeted Metabolomic Strategy for the Discovery of Biomarker of Breast Cancer

Largescale Multicenter Study of a Serum Metabolite Biomarker Panel for the Diagnosis of Breast Cancer

Integrative Analysis of Plasma Metabolomics and Proteomics Reveals the Metabolic Landscape of Breast Cancer

Biotransformation-based Metabolomics Profiling Method for Determining and Quantitating Cancer-Related Metabolites.

RRLC-MS/MS-based metabonomics combined with in-depth analysis of metabolic correlation network: finding potential biomarkers for breast cancer.

Early Breast Cancer Detection Using Untargeted and Targeted Metabolomics.

Serum Metabonomics Study on Breast Cancer with UPLC/MS

Identification of a Novel Biomarker Panel for Breast Cancer Screening

Mass Spectrometry-Based Quantitative Metabolomics Revealed A Distinct Lipid Profile In Breast Cancer Patients

Use of ultra-high performance liquid chromatography-high-resolution mass spectroscopy to profile the metabolites from the serum of patients with breast cancer

Metabolic reprogramming enables the auxiliary diagnosis of breast cancer by automated breast volume scanner

Breast Cancer Detection Using Targeted Plasma Metabolomics

An improved detection and identification strategy for untargeted metabolomics based on UPLC-MS

Metabolomic Analysis of Plasma from Breast Cancer Patients Using Ultra-High-Performance Liquid Chromatography Coupled with Mass Spectrometry: An Untargeted Study

Metabolic Discrimination of Breast Cancer Subtypes at the Single-Cell Level by Multiple Microextraction Coupled with Mass Spectrometry

Efficient Cancer Biomarker Screening and Multicancer Detection Enabled by a Multidimensional Serum Proteomic Strategy.

Application of Metabolomics by UHPLC-MS/MS in Diagnostics and Biomarker Discovery of Non-Small Cell Lung Cancer

Untargeted Saliva Metabonomics Study of Breast Cancer Based on Ultra Performance Liquid Chromatography Coupled to Mass Spectrometry with Hilic and Rplc Separations

A simplified metabolomic analysis of dried blood spots in breast cancer patients

Identification of canine mammary tumor-associated metabolites using untargeted metabolomics

Metabolomics Analysis of Multidrug-Resistant Breast Cancer Cellsin Vitrousing Methyl-Tert-butyl Ether Method